Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase II Multicenter Study of Vemurafenib (Zelboraf®) Plus Cobimetinib (Cotellic®) After Radiosurgery in Patients With Active BRAF-V600-mutant Melanoma Brain Metastases

NCT03430947 is registered in ClinicalTrials.gov with Technische Universität Dresden as lead sponsor.

NCT NCT03430947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03430947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase II Multicenter Study of Vemurafenib (Zelboraf®) Plus Cobimetinib (Cotellic®) After Radiosurgery in Patients With Active BRAF-V600-mutant Melanoma Brain Metastases
Lead sponsor
Technische Universität Dresden
Phase
Phase 2
Overall status
Terminated
Start date
July 1, 2018
Completion date
February 10, 2023
Enrollment
20 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

braf v600 mutation, brain metastases, malignant melanoma stage iv